Search

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more

The EHA Guidelines Workshop, a meaningful and successful first Series!

November 2020 – April 2021

In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

Celebrating the International Day of Women & Girls in Science

On this International Day of Women & Girls in Science, we take a moment to honor, appreciate and thank, all the women scientists at the forefront of the fight against COVID-19.

Read more

How to apply for an EHA Kick-off Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Kick-off Grant application.

Read more

Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?

During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.

Read more

Nikolai Klimko 1956-2023

Professor Nikolai Klimko 

Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023

With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more